Hot Research PM

Keryx's Promising Kidney-Disease Drug

Maxim Group initiated coverage of the biotech at Buy.

We are initiating coverage of Keryx Biopharmaceuticals with a Buy rating and $4.00 price target. We believe that there is a high probability of success associated with the outcome of the current phase III pivotal trial for Zerenex in kidney disease.

Phase III Zerenex long-term data is coming. The last patient of a large pivotal trial has completed...